<DOC>
	<DOCNO>NCT01846494</DOCNO>
	<brief_summary>The purpose study monitor cardiovascular renal health patient previously take BMS-986094 ( investigational medication hepatitis C ) comparison hepatitis C infect patient never take BMS-986094 .</brief_summary>
	<brief_title>Longitudinal Assessment Cardiovascular Renal Health Patients With Hepatitis-C ( CARE-Hep C )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<criteria>Subjects enrol base prior enrollment BMS 986094 study treatmentnaïve HCV subject know cardiovascular abnormality . 1 . All Subjects must give informed consent prior participation study . 2 . Subject participate Phase 1 Phase 2 trial BMS 986094 ( include placebo arm ) OR 3 . Subject know hepatitis C ( Control ) 1 . No previous exposure BMS 986094 2 . Treatment naive study entry ( No prior hepatitis C treatment experience time enrollment , include limit : standard interferon , pegylated interferon , ribavirin , boceprevir , telaprevir , experimental drug hepatitis C ) . Exclusion Criteria 1 . For subject participate Phase 1 Phase 2 trial BMS 986094 , exclusion criterion 2 . For control group subject without exposure BMS 986094 , follow exclusion criterion , base clinically available data , apply : 1 . Signs symptom decompensated liver disease variceal bleeding , ascites , hepatic encephalopathy , active jaundice define indirect bilirubin &gt; 2 , ALT AST laboratory value ≥ 10 time upper limit normal , evidence decompensated liver disease hepatocellular carcinoma 2 . Chronic liver disease HCV limit Hepatitis B virus ( positive test HBsAg ) , hemochromatosis , autoimmune hepatitis , alcoholic liver disease nonalcoholic fatty liver disease 3 . History liver transplantation 4 . Coinfection HIV ( positive test antiHIV Ab ) 5 . Prior history cardiomyopathy ( ejection fraction ≤ 50 % ) history heart failure 6 . Signs symptom decompensated heart failure 7 . Prior history coronary artery disease , acute myocardial infarction coronary artery revascularization ( percutaneous coronary artery bypass grafting )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>